Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: S100A9

Summary for S100A9

Gene information	Gene symbol	S100A9
	Ensembl ID	ENSG00000163220
	Entrez ID	6280
	Gene name	S100 calcium binding protein A9
	Synonyms	60B8AG\|CAGB\|CFAG\|CGLB\|LIAG\|MAC387\|MIF\|MRP-14\|MRP14\|NIF\|P14\|S100-A9
	Gene type	protein_coding
	UniProtAcc	P06702

Top

Dataset with differentially expressed gene: S100A9

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	4.52285	3.21e-02
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	1.21898	5.72e-03
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.658508	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.604576	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.560182	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-1.30479	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.55763	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	0.89018	2.68e-13
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	1.03013	3.55e-26
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.411013	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	pDCs	-0.562496	1.32e-03
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.668855	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	1.2179	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	1.46087	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.969108	2.68e-08
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	0.331119	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD4+ T cells	-0.542299	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	Mono/Macro	0.545906	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD8+ T cells	-0.391142	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.400929	1.45e-09
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.612899	4.86e-12
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-1.4539	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Malignant cells	-1.02423	3.14e-05
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.403827	1.70e-26
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-0.713049	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.465465	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	1.63333	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.600251	1.51e-16
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	B cells	-1.05449	4.39e-17
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	-0.639065	8.50e-41
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD4+ T cells	-0.654527	9.29e-08
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-1.11462	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-1.03904	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	cDCs	-1.50233	2.85e-02
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	3.54138	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-1.07287	3.71e-26
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.331734	8.00e-10
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.849948	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.677585	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	0.341221	1.66e-04
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	0.926856	1.08e-11
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD4+ T cells	0.449018	4.03e-11
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	0.665535	1.87e-42
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.834443	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	0.392627	3.63e-21
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	4.84885	0.00e+00

Top

Expression of S100A9 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to S100A9

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating S100A9

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
S100A9	hsa-miR-92a-1-5p	81.2383	NM_002965

Page: 1

Top

Motifs and transcription factors (TFs) regulating S100A9

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
S100A9	transfac_pro__M06213	ZNF267 (directAnnotation).
S100A9	tfdimers__MD00380	ARID3A; ING4 (directAnnotation).
S100A9	transfac_pro__M05304	ZBTB5 (directAnnotation).
S100A9	tfdimers__MD00412	E2F6; NR3C1 (directAnnotation).
S100A9	homer__ATTGCGCAAC_CEBP	CEBPB (inferredBy_Orthology).
S100A9	metacluster_22.4	MAFG (inferredBy_Orthology).
S100A9	hocomoco__ETV3_HUMAN.H11MO.0.D	ETV3 (directAnnotation).
S100A9	transfac_pro__M07484	DNTTIP1 (directAnnotation).
S100A9	tfdimers__MD00119	ASCL1; ATF1; ATF2; ATF3; ATF4; ATF7; CREB1; CREM; MYF5; MYF6; MYOD1; MYOG; TCF12; TCF3; TCF4 (directAnnotation).
S100A9	transfac_pro__M06733	RBAK (directAnnotation).
S100A9	taipale_tf_pairs__GCM1_FIGLA_CAGCTGNNNNNNNNTGCGGG_CAP	FIGLA; GCM1 (directAnnotation).
S100A9	metacluster_29.6	ZNF436 (directAnnotation).
S100A9	transfac_pro__M05604	ZNF143 (inferredBy_Orthology).
S100A9	swissregulon__hs__OVOL1	OVOL1 (directAnnotation).
S100A9	tfdimers__MD00359	CEBPA; CEBPB; CEBPD; CEBPE; CEBPG; STAT6 (directAnnotation).
S100A9	transfac_pro__M06828	ZNF516 (inferredBy_Orthology).
S100A9	taipale_tf_pairs__ETV5_FOXI1_TGTTGNCGGAWRN_CAP	ETV5; FOXI1 (directAnnotation).
S100A9	taipale_tf_pairs__CLOCK_EVX1_ATRATYANNNNCACGTG_CAP_repr	CLOCK; EVX1 (directAnnotation).
S100A9	metacluster_52.10	GTF3C2; ZNF436 (directAnnotation).
S100A9	transfac_public__M00291	FOXC1 (directAnnotation).
S100A9	kznf__ZNF18_Imbeault2017_OM_RCADE	ZNF18 (directAnnotation).
S100A9	tfdimers__MD00217	LTF; MZF1 (directAnnotation).
S100A9	metacluster_31.3	ZSCAN20; ZSCAN29 (directAnnotation).
S100A9	taipale_tf_pairs__ELK1_EVX1_RSCGGWANNNNYMATTA_CAP_repr	ELK1; EVX1 (directAnnotation).
S100A9	taipale_tf_pairs__TEAD4_DLX2_NRCATTCNNNNYAATTN_CAP_repr	DLX2; TEAD4 (directAnnotation).
S100A9	tfdimers__MD00463	CHURC1; DBP (directAnnotation).
S100A9	kznf__ZNF605_Imbeault2017_OM_RCADE	ZNF605 (directAnnotation).
S100A9	tfdimers__MD00581	ATF5; NKX3-2 (directAnnotation).
S100A9	transfac_pro__M06547	ZNF675 (directAnnotation).
S100A9	taipale_tf_pairs__GCM1_CEBPB_MTRSGGGNNNNNTTRCGYAAN_CAP	CEBPB; GCM1 (directAnnotation).
S100A9	taipale_tf_pairs__POU2F1_SOX2_ATTTGCATNACAATRN_CAP	POU2F1; SOX2 (directAnnotation).
S100A9	transfac_pro__M01234	PDX1 (directAnnotation).
S100A9	taipale_tf_pairs__HOXD12_FIGLA_SYMRTAAANNNNCASSTGN_CAP_repr	FIGLA; HOXD12 (directAnnotation).
S100A9	swissregulon__hs__SPI1	SPI1 (directAnnotation).
S100A9	taipale_tf_pairs__ETV2_CEBPD_RSCGGANNTTGCGYAAN_CAP_repr	CEBPD; ETV2 (directAnnotation).
S100A9	metacluster_31.6	ZNF569 (directAnnotation). ZNF569 (inferredBy_Orthology).
S100A9	transfac_pro__M02031	SPI1 (directAnnotation).
S100A9	metacluster_82.5	ZKSCAN8; ZNF205; ZNF227; ZNF594 (directAnnotation).
S100A9	transfac_pro__M04856	BATF (directAnnotation).
S100A9	transfac_pro__M06133	ZNF17 (directAnnotation).
S100A9	tfdimers__MD00515	ARID3A; KLF4 (directAnnotation).
S100A9	taipale_tf_pairs__GCM1_SOX2_RTRSGGGNNNATTGTKY_CAP_repr	GCM1; SOX2 (directAnnotation).
S100A9	transfac_pro__M01660	GABPA (directAnnotation).
S100A9	swissregulon__hs__ZKSCAN3	ZKSCAN3 (directAnnotation).
S100A9	taipale_tf_pairs__ETV2_EOMES_RCCGGANNNNNNNNNNNACACCTN_CAP_repr	EOMES; ETV2 (directAnnotation).
S100A9	transfac_pro__M01266	ELF1 (directAnnotation).
S100A9	transfac_pro__M06334	ZNF782 (directAnnotation).
S100A9	tfdimers__MD00086	ARID3A; YY1 (directAnnotation).
S100A9	metacluster_9.39	BARX1 (directAnnotation).
S100A9	transfac_pro__M06493	ZNF668 (inferredBy_Orthology).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
S100A9	"Calcium"	DB01373	small molecule
S100A9	"Zinc acetate"	DB14487	small molecule
S100A9	"Zinc chloride"	DB14533	small molecule
S100A9	"Zinc sulfate, unspecified form"	DB14548	small molecule
S100A9	"Zinc"	DB01593	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."